A Novo Nordisk weight-loss drug is safe and effective in children as young as six, according to a new company-funded study, paving the way for liraglutide to become the first treatment for obesity to be made available to the age group.
Children aged 6 to 12 using the injectable pens for just over a year saw a 7.4 per cent reduction in their body-mass index compared with those on a placebo, according to the trial.
Liraglutide is a diabetes and weight-loss treatment in the same GLP-1 class of drugs as Novo Nordisk’s blockbuster Ozempic and Wegovy treatments.
您已阅读14%（562字），剩余86%（3574字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。